Abstract
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first diagnosed with metastatic disease the 5-year survival rate is approximately 5%. To help accelerate the development of novel therapeutics and computer-based tools for optimizing individual therapy, we have collated data from 11 different clinical trials in NSCLC and developed a semi-mechanistic, clinical model of NSCLC growth and pharmacodynamics relative to the various therapeutics represented in the study. In this study, we have produced extremely precise estimates of clinical parameters fundamental to cancer modeling such as the rate of acquired resistance to various pharmaceuticals, the relationship between drug concentration and rate of cancer cell death, as well as the fine temporal dynamics of anti-VEGF therapy. In the simulation sets documented in this study, we have used the model to make meaningful descriptions of efficacy gain in making bevacizumab-antiproliferative combination therapy sequential, over a series of days, rather than concurrent.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors of this manuscript did not receive payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As the data is collated from several previous clinical trials in NSCLC, it was unnecessary to seek IRB/oversight body approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Reference Nomenclature and Abbreviations for Equations
- afolate
- The antifolate action of a cytotoxic drug i.e. pemetrexed
- apo
- Apomab aka DAB4, its chimeric derivative chDAB4, or PRO95780
- auc
- The area under the curve of drug concentration over time, usually interpreted as a measure of exposure
- bev
- Bevacizumab
- car
- Carboplatin
- cc
- Concentration, usually concentration as a function of time
- cis
- Cisplatin
- doc
- Docetaxel
- dr5
- The mechanism of action of Apomab, a monoclonal antibody against death receptor 5
- eff
- Effect
- egfr
- The egfr-based (endothelial growth factor receptor) mechanism of erlotinib
- erl
- Erlotinib
- gem
- Gemcitabine
- kk
- Rate of passage between compartments
- microt
- The microtubule-inhibition mechanisms of paclitaxel and docetaxel
- n
- Sum of primary all tumor volumes i.e. v + vi+ z1+ z2+ z3
- dnasub
- The mechanism of action of gemcitabine whereby it masquerades as a functional nucleoside only to cause masked chain termination when incorporated into DNA
- pac
- Paclitaxel
- pem
- Pemetrexed
- plat
- The class of cytotoxics whose mechanism involves platinum i.e. cisplatin, carboplatin, etc.
- Qα, Qρ
- The effects whereby certain drugs limit the rate of growth of the tumor e.g. cell cycle arrest, nutrient supply disruption, etc.
- Qγ
- The effect whereby certain drugs kill tumor cells directly
- t
- Time in days
- v
- Primary tumor volume in cm3
- vi
- Volume of tumor cells which are injured by vegf and microt drugs
- vegf
- The anti-vegf (vascular endothelial growth factor) mechanism of bevacizumab
- z1–3
- Irreversible cell death compartments
- wd
- A scaling factor between drug concentration and cytotoxic effect
- λd
- Scaling factor between drug exposure and resistance
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos